Key insights
- Johnson & Johnson will market four drugs on the TrumpRx website, following a January agreement to reduce drug prices in exchange for tariff exemptions. This may improve JNJ's market access and public image, but the financial impact on US equities is likely limited unless other major drug companies follow suit.
April 24 (Reuters) - Johnson & Johnson will start marketing four of its medications on the Trump administration’s TrumpRx website on Friday, CBS News reported.
The healthcare conglomerate voluntarily reached an agreement with the Trump administration in January to reduce drug prices for Americans, expanding access to affordable prescriptions under Medicaid and marketing its products on the TrumpRx platform in exchange for an exemption from the administration’s tariffs.
Reuters was unable to verify which four drugs were slated to be featured on the website.
Johnson & Johnson did not immediately respond to a request for comment.